This grant proposal requests the funds necessary for continued support of the General Clinical Research Center of the School of Medicine of the University of North Carolina at Chapel Hill. This facility, which was one of the very earliest GCRCs to receive federal support, has been continuously funded by the National Institutes of Health for over 30 years. The goals of the Clinical Research Center of the University of North Carolina at Chapel Hill mirror the guidelines that have been set forth by the national GCRC program. These are: a) to create an optimal setting for investigation of both normal and abnormal body function; b) to provide a facility where the cause and the natural history of human illness can be defined and where disease progression, prevention, control, and cure can be studied; c) to facilitate the rapid translation of advances in basic scientific knowledge into new or improved methods for patient care; and d) to serve as a focal point and an institutional resource where health professionals of all types can receive training in the many aspects of clinical investigation. This application contains a summary of the clinical research that has been carried out on this GCRC since its last review in 1985, and then presents the proposed research activities for the upcoming five year cycle. In addition, we have described in some detail the importance of the Clinical Research Center not just to the School of Medicine, but to the entire research community that encompasses the University of North Carolina Hospitals and all five schools of the health affairs campus of the University of North Carolina at Chapel Hill and to such federal agencies as the NIEHS and the EPA, both of which are located in close proximity to the Medical Center. Finally, we have emphasized in this application not only the clinical investigation that takes place on the GCRC, but also the vital role played by the Center in the education and training of current and future clinical investigators.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000046-33
Application #
3089351
Study Section
General Clinical Research Centers Committee (CLR)
Project Start
1974-10-01
Project End
1997-11-30
Budget Start
1992-12-01
Budget End
1993-11-30
Support Year
33
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Barber, Megan R W; Hanly, John G; Su, Li et al. (2018) Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken) 70:1294-1302
Rini, Christine; Vu, Maihan B; Lerner, Hannah et al. (2018) A qualitative study of patient and provider perspectives on using web-based pain coping skills training to treat persistent cancer pain. Palliat Support Care 16:155-169
Little, Jayne; Parker, Ben; Lunt, Mark et al. (2018) Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford) 57:677-687
Abdullah, Lubna H; Coakley, Raymond; Webster, Megan J et al. (2018) Mucin Production and Hydration Responses to Mucopurulent Materials in Normal versus Cystic Fibrosis Airway Epithelia. Am J Respir Crit Care Med 197:481-491
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Malinen, Melina M; Kauttonen, Antti; Beaudoin, James J et al. (2018) Novel In Vitro Method Reveals Drugs that Inhibit Solute Transporter Alpha/Beta (OST?/?). Mol Pharm :
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Hanly, John G; Li, Qiuju; Su, Li et al. (2018) Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care Res (Hoboken) 70:1478-1487

Showing the most recent 10 out of 782 publications